241 related articles for article (PubMed ID: 38612726)
1. Targeting Group 3 Medulloblastoma by the Anti-PRUNE-1 and Anti-LSD1/KDM1A Epigenetic Molecules.
Bibbò F; Asadzadeh F; Boccia A; Sorice C; Bianco O; Saccà CD; Majello B; Donofrio V; Bifano D; De Martino L; Quaglietta L; Cristofano A; Covelli EM; Cinalli G; Ferrucci V; De Antonellis P; Zollo M
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612726
[TBL] [Abstract][Full Text] [Related]
2. The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma.
Pajtler KW; Weingarten C; Thor T; Künkele A; Heukamp LC; Büttner R; Suzuki T; Miyata N; Grotzer M; Rieb A; Sprüssel A; Eggert A; Schramm A; Schulte JH
Acta Neuropathol Commun; 2013 May; 1():19. PubMed ID: 24252778
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of LSD1 activity blocks REST-dependent medulloblastoma cell migration.
Callegari K; Maegawa S; Bravo-Alegria J; Gopalakrishnan V
Cell Commun Signal; 2018 Sep; 16(1):60. PubMed ID: 30227871
[TBL] [Abstract][Full Text] [Related]
4. Lsd1 as a therapeutic target in Gfi1-activated medulloblastoma.
Lee C; Rudneva VA; Erkek S; Zapatka M; Chau LQ; Tacheva-Grigorova SK; Garancher A; Rusert JM; Aksoy O; Lea R; Mohammad HP; Wang J; Weiss WA; Grimes HL; Pfister SM; Northcott PA; Wechsler-Reya RJ
Nat Commun; 2019 Jan; 10(1):332. PubMed ID: 30659187
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response.
Pishas KI; Drenberg CD; Taslim C; Theisen ER; Johnson KM; Saund RS; Pop IL; Crompton BD; Lawlor ER; Tirode F; Mora J; Delattre O; Beckerle MC; Callen DF; Sharma S; Lessnick SL
Mol Cancer Ther; 2018 Sep; 17(9):1902-1916. PubMed ID: 29997151
[TBL] [Abstract][Full Text] [Related]
6. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
[TBL] [Abstract][Full Text] [Related]
7. Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma.
Alejo S; Palacios BE; Venkata PP; He Y; Li W; Johnson JD; Chen Y; Jayamohan S; Pratap UP; Clarke K; Zou Y; Lv Y; Weldon K; Viswanadhapalli S; Lai Z; Ye Z; Chen Y; Gilbert AR; Suzuki T; Tekmal RR; Zhao W; Zheng S; Vadlamudi RK; Brenner AJ; Sareddy GR
Neuro Oncol; 2023 Jul; 25(7):1249-1261. PubMed ID: 36652263
[TBL] [Abstract][Full Text] [Related]
8. Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma.
Li M; Han Y; Wang C; Kang W; Jiang W; Zhang L; Tang Y
J Exp Clin Cancer Res; 2022 Oct; 41(1):311. PubMed ID: 36273157
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic regulation of epithelial to mesenchymal transition by the Lysine-specific demethylase LSD1/KDM1A.
Ambrosio S; Saccà CD; Majello B
Biochim Biophys Acta Gene Regul Mech; 2017 Sep; 1860(9):905-910. PubMed ID: 28720390
[TBL] [Abstract][Full Text] [Related]
10. LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer.
Boulding T; McCuaig RD; Tan A; Hardy K; Wu F; Dunn J; Kalimutho M; Sutton CR; Forwood JK; Bert AG; Goodall GJ; Malik L; Yip D; Dahlstrom JE; Zafar A; Khanna KK; Rao S
Sci Rep; 2018 Jan; 8(1):73. PubMed ID: 29311580
[TBL] [Abstract][Full Text] [Related]
11. Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-β-OTX2-SNAIL via PTEN inhibition.
Ferrucci V; de Antonellis P; Pennino FP; Asadzadeh F; Virgilio A; Montanaro D; Galeone A; Boffa I; Pisano I; Scognamiglio I; Navas L; Diana D; Pedone E; Gargiulo S; Gramanzini M; Brunetti A; Danielson L; Carotenuto M; Liguori L; Verrico A; Quaglietta L; Errico ME; Del Monaco V; D'Argenio V; Tirone F; Mastronuzzi A; Donofrio V; Giangaspero F; Picard D; Remke M; Garzia L; Daniels C; Delattre O; Swartling FJ; Weiss WA; Salvatore F; Fattorusso R; Chesler L; Taylor MD; Cinalli G; Zollo M
Brain; 2018 May; 141(5):1300-1319. PubMed ID: 29490009
[TBL] [Abstract][Full Text] [Related]
12. MiR-137-3p Inhibits Colorectal Cancer Cell Migration by Regulating a KDM1A-Dependent Epithelial-Mesenchymal Transition.
Ding X; Zhang J; Feng Z; Tang Q; Zhou X
Dig Dis Sci; 2021 Jul; 66(7):2272-2282. PubMed ID: 32749639
[TBL] [Abstract][Full Text] [Related]
13. Lysine-specific demethylase (LSD1/KDM1A) and MYCN cooperatively repress tumor suppressor genes in neuroblastoma.
Amente S; Milazzo G; Sorrentino MC; Ambrosio S; Di Palo G; Lania L; Perini G; Majello B
Oncotarget; 2015 Jun; 6(16):14572-83. PubMed ID: 26062444
[TBL] [Abstract][Full Text] [Related]
14. KDM1A inhibition augments the efficacy of rapamycin for the treatment of endometrial cancer.
Venkata PP; Chen Y; Alejo S; He Y; Palacios BE; Loeffel I; Liu J; Pratap UP; Gray G; Achuthan Pillai SM; Zou Y; Lai Z; Suzuki T; Viswanadhapalli S; Palakurthi S; Tekmal RR; Vadlamudi RK; Kost E; Sareddy GR
Cancer Lett; 2022 Jan; 524():219-231. PubMed ID: 34673129
[TBL] [Abstract][Full Text] [Related]
15. The malignant brain tumor (MBT) domain protein SFMBT1 is an integral histone reader subunit of the LSD1 demethylase complex for chromatin association and epithelial-to-mesenchymal transition.
Tang M; Shen H; Jin Y; Lin T; Cai Q; Pinard MA; Biswas S; Tran Q; Li G; Shenoy AK; Tongdee E; Lin S; Gu Y; Law BK; Zhou L; Mckenna R; Wu L; Lu J
J Biol Chem; 2013 Sep; 288(38):27680-27691. PubMed ID: 23928305
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of neuronal Lysine-Specific Demethylase 1LSD1/KDM1A impairs transcriptional repression by regulating interaction with CoREST and histone deacetylases HDAC1/2.
Toffolo E; Rusconi F; Paganini L; Tortorici M; Pilotto S; Heise C; Verpelli C; Tedeschi G; Maffioli E; Sala C; Mattevi A; Battaglioli E
J Neurochem; 2014 Mar; 128(5):603-16. PubMed ID: 24111946
[TBL] [Abstract][Full Text] [Related]
17. Oncogene LSD1 is epigenetically suppressed by miR-137 overexpression in human non-small cell lung cancer.
Zhang X; Zhang X; Yu B; Hu R; Hao L
Biochimie; 2017 Jun; 137():12-19. PubMed ID: 28223039
[TBL] [Abstract][Full Text] [Related]
18. Histone methyl-transferases and demethylases in the autophagy regulatory network: the emerging role of KDM1A/LSD1 demethylase.
Ambrosio S; Ballabio A; Majello B
Autophagy; 2019 Feb; 15(2):187-196. PubMed ID: 30208749
[TBL] [Abstract][Full Text] [Related]
19. LSD1: a viable therapeutic target in cutaneous squamous cell carcinoma?
Egolf S; Capell BC
Expert Opin Ther Targets; 2020 Jul; 24(7):671-678. PubMed ID: 32379508
[TBL] [Abstract][Full Text] [Related]
20. Histone demethylase UTX/KDM6A enhances tumor immune cell recruitment, promotes differentiation and suppresses medulloblastoma.
Yi J; Shi X; Xuan Z; Wu J
Cancer Lett; 2021 Feb; 499():188-200. PubMed ID: 33253789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
